Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females

PHASE2CompletedINTERVENTIONAL

Enrollment

210

Participants

Timeline

Start Date

October 31, 1999

Primary Completion Date

September 30, 2004

Study Completion Date

September 30, 2004

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL

MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1)

IM injection

BIOLOGICAL

MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2)

IM injection

BIOLOGICAL

MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3)

IM injection

BIOLOGICAL

MEDI-517 HPV-16/18 VLP with Al(OH)3 (Formulation 4)

IM injection